AviadoBio develops gene therapies utilizing a neuroanatomy-led approach to deliver treatments directly to the central nervous system for patients with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company addresses the lack of effective therapies for these neurodegenerative disorders by maximizing therapeutic potential to potentially halt or reverse disease progression.
Funding
$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
APFounders
Product
Problem
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are devastating neurodegenerative diseases with limited or no effective treatments, significantly impacting patients and their families. Current treatment pathways face challenges in delivering drugs effectively to the central nervous system.
Solution
AviadoBio is developing gene therapies for FTD and ALS, utilizing a neuroanatomy-led approach to precisely deliver treatments directly to the central nervous system. Their approach aims to maximize the therapeutic potential of gene therapy to potentially halt or even reverse disease progression. By focusing on targeted and precise drug delivery and dosing, AviadoBio seeks to achieve maximal biodistribution to the brain and spinal cord with a favorable safety profile.
Target Audience
The primary target audience includes patients living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), as well as their families and caregivers.
Features
- Neuroanatomy-led approach for targeted delivery to the central nervous system
- Proprietary gene therapy platforms and delivery technologies
- Focus on maximal biodistribution to the brain and spinal cord
- AVB-101: Gene therapy targeting frontotemporal dementia (FTD-GRN) is in Phase 1/2 clinical trials